Objective—Diabetic postinfarction patients are at increased mortality risk compared with nondiabetic postinfarction patients. In a substantial number of these patients, diabetic cardiac neuropathy already preexists at the time of the infarction. In the current study we investigated if markers of autonomic dysfunction can further discriminate diabetic postinfarction patients into low- and high-risk groups.

Research Design and Methods—We prospectively enrolled 481 patients with type 2 diabetes who survived acute myocardial infarction (MI), were aged ≤80 years, and presented in sinus rhythm. Primary end point was total mortality at 5 years of follow-up. Severe autonomic failure (SAF) was defined as coincidence of abnormal autonomic reflex function (assessed by means of heart rate turbulence) and of abnormal autonomic tonic activity (assessed by means of deceleration capacity of heart rate). Multivariable risk analyses considered SAF and standard risk predictors including history of previous MI, arrhythmia on Holter monitoring, insulin treatment, and impaired left ventricular ejection fraction (LVEF) (50%).

Results—During follow-up, 83 of the 481 patients (17.3%) died. Of these, 24 deaths were sudden cardiac deaths and 21 nonsudden cardiac deaths. SAF identified a high-risk group of 58 patients with a 5-year mortality rate of 64.0% at a sensitivity level of 38.0%. Multivariately, SAF was the strongest predictor of mortality (hazard ratio 4.9 [95% CI 2.4–9.9]), followed by age ≥65 years (3.4 [1.9–5.8]), and LVEF ≤30% (2.6 [1.5–4.4]).

Conclusions—Combined abnormalities of autonomic reflex function and autonomic tonic activity identifies diabetic post-MI patients with very poor prognoses.

Diabetes Care 34:1833–1837, 2011

Diabetes remains one of the leading causes of death in the industrialized world despite considerable recent attention. Diabetic patients with histories of myocardial infarctions (MIs) have particularly poor prognoses (1). A substantial number of deaths in these patients occur suddenly and might thus be preventable by prophylactic implantation of implantable cardioverter defibrillators (ICDs). As implanting ICDs in all diabetic post-MI patients would not be cost-effective, further risk stratification of this patient population is necessary. At present, left ventricular ejection fraction (LVEF) is the gold standard tool for post-MI risk stratification (2). However, it is neither specific nor sensitive. This problem is not related to diabetic patients because risk stratification in the general postinfarction population suffers from the same shortcoming. Therefore, additional risk stratification tools, including the assessment of autonomic dysfunction, have been proposed for the general postinfarction population.

In diabetic postinfarction patients, autonomic function can be affected by both the infarction, including its complications, and the preexisting cardiac autonomic neuropathy (2–4). This might compromise risk-predictive value of the autonomic markers. Therefore, this study was undertaken to investigate whether markers of autonomic dysfunction are of prognostic value in the clinical setting of acute MI complicated by a preexisting diabetic cardiac neuropathy.

Heart rate turbulence (HRT) (5) and deceleration capacity (DC) (6) are Holter-based techniques that capture different aspects of autonomic control. HRT quantifies an autonomic reflex, namely the heart rate response to the transient fall of arterial pressure caused by ventricular premature complexes (VPCs). DC is supposed to be representative of tonic vagal activity. Coincidence of abnormal HRT and DC are suggestive of severe autonomic failure (SAF). In unselected post-MI patients, SAF indicated high risk of subsequent death (7). In the current study of diabetic post-MI patients, we tested the association of SAF with 5-year mortality and the improvement of risk prediction by adding SAF to the LVEF gold standard.

Research Design and Methods—Between January 1996 and March 2005, survivors of acute MI (<4 weeks) were enrolled at two large university hospitals, the German Heart Centre and the Klinikum Rechts der Isar, both located in Munich, Germany. Patients were included if they suffered from type 2 diabetes, were aged ≤80 years, presented in sinus rhythm, and did not meet the criteria for secondary ICD therapy (i.e., had cardiac arrest or documented sustained ventricular tachycardia). Type 2 diabetes was considered present if a patient was already diagnosed
Assessment of reflex and tonic autonomic markers

In all patients, 24-h Holter electrocardiograms were recorded within 2 weeks of enrollment. All recordings were routinely processed using standard commercial equipment (Oxford Excel Holter system, Oxford Instruments; Pathfinder 700, Reynolds Medical; and Mortara Holter system, Mortara Instrument) to obtain the sequence of individual R-R intervals together with the distinction of sinus rhythm beats and ventricular premature complexes.

HRT is composed of an initial heart rate acceleration followed by a subsequent heart rate deceleration (8). The two phases of HRT are quantified by two numerical descriptors, turbulence onset (TO) and turbulence slope (TS). HRT was considered abnormal if both TO and TS were abnormal (TO ≥0% and TS ≥2.5 ms per heartbeat interval, respectively) (8). DC was considered abnormal if ≤4.5 ms (6).

The association of HRT and DC with autonomic abnormalities was previously reported (6,9).

Definition of categories of autonomic dysfunction

Normal autonomic function (NAF) was assumed if both HRT and DC were normal. Mild autonomic failure (MAF) was assumed if only one of HRT and DC was normal while the other was abnormal. Severe autonomic failure (SAF) was assumed if both HRT and DC were abnormal.

Other risk predictors

Other evaluated risk predictors included age, sex, history of previous MI, standard deviation of normal-to-normal heartbeat intervals (SDNN) (10), mean heart rate, arrhythmias during Holter monitoring, insulin dependency, and LVEF. LVEF was assessed by left ventricular angiography or biplane echocardiography. In the latter case, a phased-array system (Sonos 5500, Hewlett Packard) was used.

Variables were dichotomized at predefined cutoff values based on previous publications: LVEF ≤30%, age ≥65 years, SDNN ≤70 ms, mean heart rate ≥75 bpm, single VPCs ≥10 per h, and presence or absence of nonsustained ventricular tachycardia (nsVT) (11). The latter two parameters defined arrhythmia categories: negative (<10 VPCs per h and absence of nsVT) and positive (≥10 VPCs per h or presence of nsVT in 24 h). Renal impairment was defined as the estimated glomerular filtration rate (eGFR) ≤60 ml/min/1.73 m² (12).

Study end points

If a patient died during follow-up, the reason for death was verified from hospital and autopsy records and from either the primary physician or those witnessing the death. An independent end point committee adjudicated the mode of death. Deaths were categorized as cardiac and noncardiac. Cardiac deaths were further categorized as sudden and nonsudden. Cardiac death was defined as sudden if it was a witnessed death occurring within 60 min of the onset of new symptoms unless 1) there was an obvious noncardiac cause, or 2) if it was an unwitnessed death in the absence of preexisting progressive circulatory failure or other causes of death, or 3) if it was a death during attempted resuscitation. The primary end point of the study was all-cause mortality within the first 5 years of follow-up; secondary end points were cardiac and sudden cardiac death also within the first 5 years of follow-up.

Data analysis and statistics

We investigated both the association of the autonomic dysfunction categories with outcome and the improvement of risk prediction by adding these categories to the current LVEF-based standard of risk prediction. Continuous variables are presented as median and interquartile range; qualitative data are expressed as percentages. Mortality rates were estimated by the Kaplan-Meier method (13) and compared by two-sided log-rank test.

Secondary end points (cardiac death and sudden death) were analyzed with competing risk models (14) using R and compared with the procedure proposed by Gray (15). Multivariable analyses were performed using a two-sided Cox proportional hazards model with enter procedure of all risk predictors considered (Table 2). Hazard ratios (HRs) are presented with 95% CIs. The diagnostic properties of the different prognostic systems are characterized by sensitivity, specificity, and predictive values calculated to reflect the number of expected deaths in case of censored data (16). The change in the difference in the predicted probabilities of the outcome after introducing SAF to LVEF was estimated by the integrated discrimination index (IDI) (17), where a better model is reflected by a greater difference in the predicted probabilities. Differences were considered statistically significant if P < 0.05 (SPSS 18.0, SPSS Inc.).

RESULTS—During the recruitment period, 481 patients were enrolled. Table 1 shows the clinical characteristics of the patients. The median of creatine kinase maximum was 1,114 units/L. Median LVEF was 51%. Percutaneous coronary interventions were performed in 89% of the patients. The adjuvant medication consisted of aspirin in 99%, β-blockers

| Characteristic | n = 481 |
|----------------|---------|
| Age (years)    | 65 (57–72) |
| Female sex     | 137 (28) |
| Oral antidiabetic drugs | 276 (57) |
| Insulin dependency | 139 (29) |
| History of previous MI | 75 (16) |
| CKmax (U/l)    | 1,114 (494–2,400) |
| Creatinine (mg/dL) | 1.1 (0.9–1.3) |
| eGFR (ml/min/1.73 m²) | 70 (55–88) |
| LVEF (%)       | 51 (42–59) |
| VPC (counts per h) | 0.5 (0.1–3.6) |
| Nonsustained VT | 39 (8) |
| Abnormal HRT   | 73 (15) |
| DC ≤4.5 ms     | 250 (52) |
| NAF            | 216 (45) |
| MAF            | 207 (43) |
| SAF            | 58 (12) |

Data are median (interquartile range) or n (%). CKmax: creatine kinase maximum; VT, ventricular tachycardia; abnormal HRT, abnormality defined as coincidence of both abnormal turbulence onset and abnormal turbulence slope.

Table 1—Patients characteristics of the study population
in 94%, ACE inhibitors in 94%, and statins in 85%. Two hundred seventy-six (57.4%) of the patients received oral antidiabetic drugs; 139 (28.9%) of the patients were treated with insulin. Follow-up information was collected on all patients. Six patients were lost to follow-up. They were censored at the date of last contact. During the median follow-up of 3.9 years, 83 diabetic patients died; out of these, 21 deaths were classified as nonsudden cardiac and 24 as sudden cardiac deaths. Another 28 deaths were classified as noncardiac deaths, while the mode of death could not be specified in 10 cases.

Association of autonomic dysfunction with the primary end point
Fifty-eight patients had SAF (12.1%), 207 patients had MAF (43.0% [abnormal DC in 192 patients, abnormal HRT in 15 patients]), and 216 patients had NAF (44.9%).

In univariable analysis, all risk factors with the exception of sex were significantly associated with 5-year mortality; SAF provided the highest HR of 11.2 (95% CI 6.1–20.5) (Table 2). In MAF and NAF patients, the probabilities of death within 5 years were 2.7 (1.5–4.9) and 2.3 (1.4–3.5) (Table 2). In SAF patients, probability of death within 5 years was 64.0% (positive predictive value). SAF provided the highest HR of 11.2 (6.1–20.5) (95% CI, 0.0001). In the large group of diabetic post-MI patients, SAF was also a statistically significant predictor of cardiac death and sudden cardiac death (Fig. 1B and C). Probability of cardiac death within 5 years was 3.8% in NAF patients. In MAF and SAF patients, these numbers were 9.7 and 42.8%, respectively. Probability of sudden death within 5 years was 2.1, 5.9, and 19.5% in NAF, MAF, and SAF patients, respectively.

Improvement of risk prediction by SAF
If SAF was added to LVEF, a significant improvement in performance of the risk stratification model was observed (IDI, 0.022; P < 0.0001). In the large group of patients with LVEF > 30%, SAF identified a patient subgroup of similar size and mortality risk as patients with depressed LVEF (Fig. 2).

LVEF ≤30% occurred in 38 patients. Of these, 20 patients died during the follow-up period. Another 63 patients died despite having LVEF > 30%. These numbers translate to a positive predictive value of 57% at a sensitivity level of 22% (Table 3).

Risk prediction was more precise if LVEF and SAF were used in combination. Eighty-two patients fulfilled the criterion “LVEF ≤30% or SAF.” Out of these, 41 patients died during the follow-up period. Another 42 patients died despite having neither LVEF ≤30% nor SAF. These numbers translate to a positive predictive value of 58% at a sensitivity level of 48% (Table 3). The increase in sensitivity by adding SAF to LVEF from 22 to 48% was statistically significant (P < 0.0001).

Comparable improvements of sensitivity without compromising positive predictive accuracies were observed with secondary end points (Table 3).

CONCLUSIONS—In our population of diabetic post-MI patients, SAF was strongly associated with 5-year mortality.

Table 2—Uni- and multivariable analyses for prediction of total mortality within 5 years of follow-up

|                | Univariable analysis | Multivariable analysis |
|----------------|----------------------|------------------------|
|                | HR (95% CI)          | P value                |
| Age ≥65 years  | 3.6 (2.2–6.0)        | <0.0001                |
| Female sex     | 1.4 (0.9–2.2)        | 0.150                  |
| Previous MI    | 2.4 (1.5–3.9)        | <0.0001                |
| Arrhythmia     | 2.0 (1.3–3.2)        | 0.002                  |
| LVEF ≤30%      | 4.7 (2.8–7.8)        | <0.0001                |
| Insulin dep.   | 1.6 (1.0–2.5)        | 0.045                  |
| Mean heart rate| 2.3 (1.4–3.5)        | <0.0001                |
| eGFR ≤70 ms    | 2.3 (1.5–3.6)        | <0.0001                |
| MAF            | 2.7 (1.5–4.9)        | 0.001                  |
| SAF            | 11.2 (6.1–20.5)      | <0.0001                |

Table 3—Mortality rates, sensitivities, and specificities for prediction of all-cause mortality, cardiac mortality, and sudden cardiac death in high-risk groups

|                | LVEF ≤30% | SAF | LVEF ≤30% or SAF | LVEF ≤30% and SAF |
|----------------|-----------|-----|------------------|-------------------|
| n              | 38        | 58  | 82               | 14                |
| Prediction of all-cause mortality at 5 years |           |     |                  |                   |
| All-cause deaths | 20        | 31  | 41               | 10                |
| Mortality rate (%) | 57.2      | 64.0 | 58.2             | 76.2              |
| Sensitivity (%)     | 21.7      | 38.0 | 47.7             | 10.6              |
| Specificity (%)     | 95.7      | 94.6 | 90.9             | 99.1              |
| PPV (%)             | 57.2      | 64.0 | 58.2             | 76.2              |
| Prediction of cardiac mortality at 5 years |           |     |                  |                   |
| All-cause deaths | 12        | 21  | 28               | 5                 |
| Mortality rate (%) | 40.5      | 48.1 | 43.3             | 55.9              |
| Sensitivity (%)     | 28.3      | 49.2 | 65.3             | 14.1              |
| Specificity (%)     | 94.7      | 92.9 | 88.8             | 98.5              |
| PPV (%)             | 40.5      | 48.1 | 43.3             | 55.9              |
| Prediction of sudden cardiac mortality at 5 years |           |     |                  |                   |
| All-cause deaths | 6         | 10  | 15               | 1                 |
| Mortality rate (%) | 25.2      | 24.2 | 25.9             | 14.3              |
| Sensitivity (%)     | 30.9      | 44.7 | 69.0             | 6.7               |
| Specificity (%)     | 93.7      | 90.2 | 86.2             | 97.3              |
| PPV (%)             | 25.0      | 24.2 | 25.9             | 14.3              |

PPV, positive predictive value.
Autonomic markers in patients with diabetes

Twelve percent of all patients showed signs of SAF and had a very poor prognosis; two out of three of these patients died within 5 years. SAF was also strongly associated with cardiac death and sudden death. Surprisingly, almost half of the population was in the NAF category with no signs of autonomic failure. Their 5-year mortality rates were low at 8.9% for death by any cause, 3.8% for cardiac death, and 2.1% for sudden death.

The addition of SAF to the standard risk model improved the risk prediction in diabetic post-MI patients. Compared with the LVEF ≤30% alone, the combination of SAF or LVEF ≤30% more than doubled the sensitivity of all-cause mortality prediction while practically preserving the positive predictive value.

In a diabetic post-MI patient, autonomic function can be affected by sequela of diabetes, by sequela of MI, or by a combination of both. Either pathology, i.e., infarction and diabetes-related autonomopathy, has been separately linked to an increased mortality risk (18,19). A substantial fraction of diabetic post-MI patients presenting with SAF might suffer from a combination of both. We hypothesize that in every individual there is autonomic defense that has a "reserve" and thus remains functional even if partially damaged by different pathologies. When different pathologies are present at the same time, the reserve is exhausted and the autonomic defense might be lost completely.

There are examples where coincidence of different autonomopathies is associated with poor outcome. Such examples include the combination of depression and MI (20), the combination of depression and end-stage renal disease (21), or the combination of diabetes and end-stage renal disease (22).

Our study has important clinical implications. Patients with SAF should receive intensive cardiac therapy based on a multifactorial approach including tight ambulatory monitoring, regular screening for progression of coronary artery disease, optimum medical therapy of heart failure, and finally prophylactic implantation of a cardioverter defibrillator.

In this context of note, diabetic post-MI patients, who generally are sicker and at higher risk of subsequent death than nondiabetic patients, benefited equally well from ICD therapy (23). Our findings also have important implications for the majority of patients with NAF. Because these patients are at very low risk for adverse events, costly and potentially hazardous therapies can be safely avoided.

Any novel risk marker has to be tested against the accepted gold standard for its additive predictive value. In postinfarction risk assessment, LVEF is such a gold standard at present. By adding SAF to LVEF, risk prediction improved significantly. Importantly, in a subset of patients without severely impaired LVEF, SAF identified a substantial number of patients with mortality risk similar to patients with depressed LVEF. As a consequence, a twofold increase in sensitivity was gained without sacrificing specificity.

Limitations of our study should also be recognized. Because we have no information about autonomic status prior to the infarction, we cannot make definite statements about the relative contributions of diabetes-related and infarction-related autonomopathy. Moreover, we have no detailed information about glycemic status, HbA1c, and changes of antidiabetic therapy after hospital discharge. We investigated diabetic survivors of myocardial infarction; we therefore cannot make statements about clinical usefulness of SAF in the general diabetic population. We did not perform reflex tests as suggested by Ewing et al. (24).
Thus, we are not able to compare their usefulness with that of SAF. Our results are limited to patients aged \( \leq 80 \) years and should not be extrapolated to older patients. Finally, by its signal processing nature, SAF assessment is limited to patients in primarily sinus rhythm.

In conclusion, our study shows that among patients with diabetes and recent MI, presence of SAF is associated with an increased risk of total mortality.

Acknowledgments—G.S. received grants from the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (BMBWF; 13N/7073/7), the Fonds zur Förderung der Wissenschaftlichen Forschung, and the Deutsche Forschungsgemeinschaft (SFB 386). These sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. G.S. holds patents on HRT and DC; both licensed to GE Healthcare or writing of the manuscript. G.S. holds patents and has a consultancy agreement with Medtronic and holds a consultancy agreement for research grants from both GE Healthcare and Medtronic (HRT patent serial numbers DE 19749393.9, EU 1028652, US 6496722; 13N/7073/7, EU 02808173.5; US 7200528). He also received research grants from both GE Healthcare and Medtronic and holds a consultancy agreement with Medtronic. No other potential conflicts of interest relevant to this article were reported.

The study concept and design were by P.B., A.B., and G.S. Acquisition of the data were by P.B., A.B., and K.M.H. Calculation of risk markers was by A.M. Analysis and interpretation of the data were by P.B., A.B., M.M., and G.S. Statistical analysis was by K.U. The main composition of the manuscript was by A.B., M.M., and G.S. Critical revisions to the manuscript and contributions to discussion were by K.M.H. N.J. reviewed and edited the manuscript and contributed to discussion. Final approval of the manuscript was by all authors.

References

1. Halfner SM, Lehto S, Rönnenmaa T, Pyörälä K, Lalkso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:220–234

2. Epstein AE, DiMarco JP, Ellenbogen KA, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities.

3. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553–1579

4. Viñik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115:387–397

5. Bauer A, Malik M, Schmidt G, et al. Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: International Society for Holter and Noninvasive Electrophysiology Consensus. J Am Coll Cardiol 2008;52:1353–1365

6. Bauer A, Kannelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 2006;367:1674–1681

7. Bauer A, Barthel P, Schneider R, et al. Improved stratification of autonomic regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk). Eur Heart J 2009;30:576–583

8. Schmidt G, Malik M, Barthel P, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 1999;353:1390–1396

9. Lewek J, Wranicz-JK, Guzik P, Chudzik M, Ruta J, Cygankiewicz I. Clinical and electrocardiographic covariates of deceleration capacity in patients with ST-segment elevation myocardial infarction. Cardiol J 2009;16:528–534

10. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043–1065

11. Barthel P, Schneider R, Bauer A, et al. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 2003;108:1221–1226

12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461–470

13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481

14. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695–706

15. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141–1154

16. Wolf P, Schmidt G, Ullm K. The use of ROC for defining the validity of the prognostic index in censored data. Stat Probab Lett 2011;81:783–791

17. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157–172; discussion 207–212

18. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ, ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478–484

19. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26:1895–1901

20. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001;104:2024–2028

21. Kojima M, Hayano J, Fukuta H, et al. Loss of fructal heart rate dynamics in depressive hemodialysis patients. Psychosom Med 2008;70:177–185

22. Giordano M, Manzella D, Paolillo G, Caliendo A, Varricchio M, Giordano C. Differences in heart rate variability parameters during the post-dialytic period in type II diabetic and non-diabetic ESRD patients. Nephrol Dial Transplant 2001;16:566–573

23. Wittenberg SM, Cook JR, Hall WJ, McNitt S, Zareba W, Moss AJ. Multicenter Automatic Defibrillator Implantation Trial. Comparison of efficacy of implanted cardioverter-defibrillator in patients with versus without diabetes mellitus. Am J Cardiol 2005;96:417–419

24. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980;49:95–108

Barthel and Associates